DeepMed Research

Laboratorios Sophia, S.A. de C.V.

🇲🇽Mexico

Country: 🇲🇽Mexico

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Tolerability of PRO-185

Phase 1

Completed

Conditions: Hyperemia Eye

Interventions: Drug: Naphazoline / Hypromellose Ophthalmic

First Posted Date: 2022-07-22

Last Posted Date: 2023-12-12

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 22

Registration Number: NCT05470868

Locations: 🇲🇽
IIMET Investigación e Innovación en Medicina Translacional, Guadalajara, Jalisco, Mexico

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

Phase 3

Recruiting

Conditions: Diabetic Macular Edema

Interventions: Biological: Bevacizumab
Biological: Lucentis®

First Posted Date: 2022-02-01

Last Posted Date: 2025-03-04

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 442

Registration Number: NCT05217680

Locations: 🇨🇴
Fundación Oftalmológica Nacional, Bogotá, Colombia
🇲🇽
SalaUno Salud, S.A.P.I. de C.V., Ciudad de Mexico, Mexico

Phase IV Clinical Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.

Phase 4

Completed

Conditions: Dry Eye

Interventions: Drug: Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%
Drug: Sodium hyaluronate 0.15%
Drug: Sodium hyaluronate 0.4%

First Posted Date: 2021-01-11

Last Posted Date: 2024-01-05

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 135

Registration Number: NCT04702776

Locations: 🇲🇽
Unidad Clínica de Bioequivalencia, S. de R.L. de C.V., Guadalajara, Jalisco, Mexico

Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

Phase 4

Terminated

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Dorzolamide-timolol-brimonidine and latanoprost
Drug: Dorzolamide-timolol and latanoprost

First Posted Date: 2021-01-11

Last Posted Date: 2023-12-12

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 28

Registration Number: NCT04702789

Locations: 🇲🇽
Servicios Médicos y de Investigación Clínica InspirePharma S. de R.L.de C.V., Monterrey, Mexico

Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used During Phacoemulsification, Compared to Healon® EndoCoat.

Phase 1

Completed

Conditions: Phacoemulsification
Age-related Cataract

Interventions: Device: Sodium hyaluronate 3%

First Posted Date: 2021-01-11

Last Posted Date: 2022-01-11

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 36

Registration Number: NCT04702802

Locations: 🇲🇽
SalaUno Salud, S.A.P.I. de C.V., Ciudad de mexico, Mexico

Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK)

Phase 4

Completed

Conditions: Photorefractive Keratectomy
Corneal De-epithelialization

Interventions: Drug: Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
Drug: Sodium Hyaluronate Ophthalmic 0.4%

First Posted Date: 2021-01-11

Last Posted Date: 2024-04-03

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 88

Registration Number: NCT04704518

Locations: 🇲🇽
Aris Vision Institute de Guadalajara, S. C., Guadalajara, Jalisco, Mexico

Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.

Phase 2

Completed

Conditions: Dry Eye

Interventions: Drug: Sodium Hyaluronate Ophthalmic 0.4% QID
Drug: Sodium Hyaluronate Ophthalmic 0.4% BID
Drug: Sodium Hyaluronate Ophthalmic 0.4% Six times per day

First Posted Date: 2021-01-11

Last Posted Date: 2022-12-28

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 141

Registration Number: NCT04704531

Locations: 🇲🇽
Instituto Jalisciense del Metabolismo, S.C., Guadalajara, Jalisco, Mexico

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+

Phase 1

Completed

Conditions: Ocular Surface
Ocular Comfort
Safety
Tolerability

Interventions: Drug: Bepotastine Besilate

First Posted Date: 2021-01-05

Last Posted Date: 2022-01-11

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 22

Registration Number: NCT04693429

Locations: 🇲🇽
Unidad Clínica de Bioequivalencia, S. de R.L. de C.V., Guadalajara, Jalisco, Mexico

Clinical Trial to Compare the Safety and Efficacy of Nanodrop®

Phase 1

Completed

Conditions: Dry Eye

Interventions: Drug: Nanodrop®
Drug: Systane Balance

First Posted Date: 2019-10-02

Last Posted Date: 2022-12-28

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 126

Registration Number: NCT04111965

Locations: 🇲🇽
Catarata y Glaucoma de Occidente, Guadalajara, Jalisco, Mexico
🇲🇽
Centro Potosino de Investigación Médica SC, San Luis Potosí, Mexico
🇲🇽
Jose Navarro Partida, Guadalajara, Jalisco, Mexico

and more 3 locations

Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution

Phase 1

Completed

Conditions: Dry Eye

Interventions: Drug: lagricel ofteno multidose
Drug: lagricel ofteno single dose

First Posted Date: 2019-09-09

Last Posted Date: 2021-05-03

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 34

Registration Number: NCT04081610

Locations: 🇲🇽
Biomedical research G & LS de RL de CV, Guadalajara, Jalisco, Mexico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy